NCT04495257View on ClinicalTrials.gov

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

February 28, 2026

Conditions
Advanced MelanomaRenal Cell Carcinoma
Interventions
DRUG

Nivolumab

Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter

DRUG

Ipilimumab

Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments

DRUG

APX005M

APX005M 0.3mg/kg intravenously (IV) every 3 weeks

Trial Locations (2)

06519

Yale Cancer Center, New Haven

06520

Yale New Haven Hospital, New Haven

All Listed Sponsors
collaborator

Apexigen America, Inc.

INDUSTRY

lead

Yale University

OTHER

NCT04495257 - A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | Biotech Hunter | Biotech Hunter